San Yuan Biological (301206.SZ): Nongfu Spring is one of the company's important clients.
Sanen Biology (301206.SZ) stated on the investor interaction platform on September 9th that Nongfu Spring is one of the company's important customers and the two parties have maintained a long-term stable cooperative relationship. Regarding the specific purchasing situation of major customers, the company will strictly follow the relevant disclosure regulations for compliance disclosure.
Jefferies Keeps Their Hold Rating on Nongfu Spring Co., Ltd. Class H (9633)
Bullish on Nongfu Spring's Tea Segment Growth Despite Market Challenges: Maintaining Buy Rating
Nongfu Spring (9633.HK): Down-to-earth and healthy development
Event: The company releases its 2024 interim performance, achieving a revenue of 22.173 billion yuan, a year-on-year increase of 8.4%, and a net income attributable to the parent company of 6.24 billion yuan, a year-on-year increase of 8.0%. Comments: Influenced by online public opinion, packaged drinking water revenue
Data Revealed | What did Beishui buy in August? Continuously increased holdings of Tencent by nearly 6.2 billion Hong Kong dollars, and sold hsbc holdings for over 1.8 billion Hong Kong dollars.
In August, the cumulative turnover of southbound funds was HKD 622.476 billion, a significant decrease of HKD 118 billion compared to July. In addition, the net inflow of southbound funds in this month was HKD 41.876 billion, a decrease of about HKD 6 billion compared to July, and lower than the average for the first 8 months.
Nongfu Spring (09633.HK): Sugar-free tea hedges against water consumption decline, while beverage competitiveness continues to strengthen.
The company announced its 1H24 performance, which met our expectations. The revenue reached 22.17 billion yuan, a year-on-year increase of +8.4%; the net income attributable to shareholders reached 6.24 billion yuan, a year-on-year increase of +8.0%. The performance met our expectations. The development trend is sugar-free.